Previous 10 | Next 10 |
Theravance Biopharma (TBPH): Q3 GAAP EPS of -$1.16 misses by $0.15.Revenue of $18.26M (+46.9% Y/Y) misses by $0.32M.Press Release For further details see: Theravance Biopharma EPS misses by $0.15, misses on revenue
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update - YUPELRI® (revefenacin) share of the nebulized COPD market increased to 17.4% through July 2020 (up from 16% in April 2020) and achieved brand profitability on a stand-alon...
Projecting Innoviva's earnings is pretty easy. For professional investors, it's even easier. Yet the stock fluctuates like crazy, and often, the highest volatility comes when earnings have just been revealed. The sometimes evident disconnect between market action and certain funda...
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 PR Newswire DUBLIN, Oct. 22, 2020 DUBLIN , Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily ...
YTD shares of Theravance Biopharma ([[TBPH]] +10.1%) have plunged more than 30%, Morgan Stanley's analyst Vikram Purohit sees an attractive entry point, as the stock is "consistently trading" at a significant discount to his estimate of a base business value of about $23/share. The ...
Soon after the COVID-19 outbreak in the U.S., Theravance advanced a nebulized pan-JAK inhibitor to treat severe coronavirus infections. Here's why I don't believe it will be a game changer, neither for the world nor for Theravance. Theravance itself does not seem to put much faith...
A special purpose acquisition company (SPAC) is a publicly traded shell company that raises capital with the intent of acquiring a private business. SPACs have become an intriguing alternative for companies that want to go public because they allow that to happen much faster than with an init...
DUBLIN , Sept. 1, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations as follows: Mo...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 08/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Theravance Biopharma, Inc. (TBPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Gail Cohen – Vice President, Corporate Communications and Investor Relations Rick Winningham – Chief Executive Officer Frank Pasqualone – Chief C...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...